Moolec Science (MLEC) and Its Rivals Head to Head Contrast

Moolec Science (NASDAQ:MLEC) is one of 673 publicly-traded companies in the “Holding & other investment offices” industry, but how does it contrast to its rivals? We will compare Moolec Science to similar companies based on the strength of its dividends, valuation, earnings, profitability, institutional ownership, analyst recommendations and risk.

Insider and Institutional Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 54.2% of shares of all “Holding & other investment offices” companies are held by institutional investors. 19.9% of Moolec Science shares are held by company insiders. Comparatively, 26.8% of shares of all “Holding & other investment offices” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Moolec Science and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-97.95%	-27.91%
Moolec Science Competitors	-18.23%	-43.18%	-0.34%

Analyst Recommendations

This is a summary of recent recommendations for Moolec Science and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	128	730	961	19	2.47

Moolec Science currently has a consensus price target of $6.00, indicating a potential upside of 582.52%. As a group, “Holding & other investment offices” companies have a potential upside of 51.26%. Given Moolec Science’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Moolec Science is more favorable than its rivals.

Volatility and Risk

Moolec Science has a beta of -0.54, indicating that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s rivals have a beta of 0.03, indicating that their average stock price is 97% less volatile than the S&P 500.

Valuation and Earnings

This table compares Moolec Science and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.62 million	-$7.31 million	-4.40
Moolec Science Competitors	$1.02 billion	$81.17 million	62.31

Moolec Science’s rivals have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Moolec Science rivals beat Moolec Science on 10 of the 13 factors compared.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.